关于《同时、单颗粒测量尺寸与载药量为药物递送纳米颗粒结构提供见解》的致编辑信
Letter to the Editor Concerning "Simultaneous, Single-Particle Measurements of Size and Loading Give Insights into the Structure of Drug-Delivery Nanoparticles"
AI总结：
本文致信指出单颗粒尺寸测量中的过度方差误差会损害纳米颗粒应用准确性，并建议采用测量误差模型解决该普遍问题。
摘要：
单颗粒尺寸测量中令人困扰的过度方差误差降低了从纳米颗粒产品质量控制到纳米塑料副产物危害评估等应用的准确性。脂质纳米颗粒在疫苗和药物递送中的特殊重要性促使了对ACS Nano上一篇论文的评论。在参考文献1中，纳米颗粒标准的基准测量表现出尺寸分布的巨大误差，这与验证声明相矛盾。此类误差可能使作为脂质纳米颗粒分子载药量光学代理的荧光强度相关性产生偏差，并从强度-尺寸数据的幂律模型中得出误导性见解。展望未来，测量误差模型有潜力解决这一普遍存在的问题。
英文摘要：
The vexing error of excess variance in the sizing of single particles degrades accuracy in applications ranging from quality control of nanoparticle products to hazard assessment of nanoplastic byproducts. The particular importance of lipid nanoparticles for vaccine and medicine delivery motivates this comment on a publication$^{\textrm{1}}$ in ACS Nano. In ref 1, the benchmark measurements of a nanoparticle standard manifest large errors of the size distribution that contradict the claim of validation. Such errors can bias the correlation of fluorescence intensity as an optical proxy for the molecular loading of lipid nanoparticles and give misleading insights from power-law models of intensity$-$size data. Looking forward, measurement error models have the potential to address this widespread issue.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
